Welcome to our dedicated page for EVOGENE LTD. news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on EVOGENE LTD. stock.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a leading computational biology company leveraging big data and artificial intelligence to revolutionize the development of life-science-based products. The company, headquartered in Rehovot, Israel, employs cutting-edge technologies to increase the probability of success while reducing development time and cost across multiple market segments including human health, agriculture, and industrial applications. Evogene has established three unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - each focused on products based on microbes, small molecules, and genetic elements respectively.
The company operates through several subsidiaries that utilize these tech-engines:
- Biomica Ltd.: Develops microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
- Lavie Bio Ltd.: Focuses on microbiome-based ag-biologicals to enhance crop yield and sustainability.
- AgPlenus Ltd.: Innovates in sustainable crop protection products.
- Canonic Ltd.: Develops medical cannabis products.
- Casterra Ag Ltd.: Produces high-yield castor seeds for biofuels and other industrial uses.
Evogene's recent achievements include securing new seed production agreements for Casterra, advancing clinical trials for Biomica's immuno-oncology candidate BMC128, and extending validation trials for Lavie Bio's biofungicides in collaboration with Bayer AG. Evogene has been proactive in addressing its Nasdaq listing compliance and continues to prioritize innovation through strategic partnerships and collaborative ventures. For more information, please visit www.evogene.com.
Rhea-AI Summary
AgPlenus Ltd, a subsidiary of Evogene Ltd., appoints Dr. Dan Jacob Gelvan as CEO, bringing extensive experience in science and technology sectors. Dr. Gelvan's leadership aims to drive growth and innovation in sustainable crop protection products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary
AgPlenus Ltd., a subsidiary of Evogene Ltd., collaborates with Bayer AG to develop a sustainable herbicide using AI technology. The collaboration aims to address weed resistance challenges in agriculture by designing a novel Mode-of-Action herbicide targeting the APTH1 protein.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.37%
Tags
-
Rhea-AI Summary
Syngenta Crop Protection and Lavie Bio Ltd., a subsidiary of Evogene Ltd., announce a collaboration to develop new biological insecticidal solutions to combat global crop challenges caused by insects. The agreement combines Lavie Bio's technology platform with Syngenta's research and commercialization capabilities to address the $70 billion annual economic impact of insect damage on crops.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
Rhea-AI Summary
Evogene Ltd. (EVGN) and Verb Biotics LLC. have entered into a collaboration agreement to develop new strains of probiotic bacteria that produce highly sustainable quantities of microbial metabolites, aiming to improve human health and vitality. The probiotics market is expected to double and reach approximately $114 billion by 2031, creating significant opportunities for growth. The financial terms of the agreement are not disclosed. The collaboration combines Evogene's tech-engine MicroBoost AI with Verb Biotic's access to the genomes of various microbial strains, generating excellent synergy. The collaboration underscores Evogene's strategic commitment to leveraging AI tech-engines in new areas and opens doors for additional sectors in the life sciences industry to benefit from their powerful technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
News
Rhea-AI Summary
Biomica Ltd., a subsidiary of Evogene Ltd. (EVGN), announced that its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain. The summit will focus on microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up. Dr. Haber will join industry panel discussions and be available for one-on-one meetings at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
-
News
Rhea-AI Summary
Biomica Ltd., a subsidiary of Evogene Ltd., has completed enrollment for its Phase I clinical trial evaluating the safety and tolerability of its microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor immunotherapy for patients with NSCLC, melanoma, or RCC. The study, conducted in Israel, is on track with preliminary results, and the first data point readout is expected in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.2%
Tags
Rhea-AI Summary
Biomica Ltd. (EVGN) to Participate in JP Morgan 42nd Annual Healthcare Week and Biotech Showcase Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary
Casterra Ag Ltd. (EVGN) announces the appointment of Mr. Yoash Zohar as the new CEO to lead the company's operational expansion, with a focus on increasing castor seed production capacity to support the bio-diesel industry's growing needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.93%
Tags
-
Rhea-AI Summary
Lavie Bio Ltd. (EVGN) announces an exclusive distribution agreement with WinField United Canada for its bio-inoculant seed treatment Yalos™, targeting spring wheat, durum, and barley crops in Canada. The partnership supports Lavie Bio's 2024 sales growth plan and aims to offer a 4:1 return on investment for farmers, given current market values.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.07%
Tags
Rhea-AI Summary
Lavie Bio Ltd. (EVGN) to Expand Yalos™ Product Line to Include Durum and Barley, Achieving 8.3% and 6.6% Production Improvement Respectively in Field Trials, Exceeding Industry Standards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
FAQ
What is the current stock price of EVOGENE LTD. (EVGN)?
The current stock price of EVOGENE LTD. (EVGN) is $1.68 as of November 18, 2024.
What is the market cap of EVOGENE LTD. (EVGN)?
The market cap of EVOGENE LTD. (EVGN) is approximately 9.3M.
What does Evogene Ltd. do?
Evogene Ltd. is a computational biology company that uses AI and big data to develop life-science-based products in human health, agriculture, and industrial applications.
Where is Evogene Ltd. headquartered?
Evogene Ltd. is headquartered in Rehovot, Israel.
What are Evogene's main technology platforms?
Evogene has three main tech-engines: MicroBoost AI for microbes, ChemPass AI for small molecules, and GeneRator AI for genetic elements.
Who are some of Evogene's subsidiaries?
Evogene's subsidiaries include Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., Canonic Ltd., and Casterra Ag Ltd.
What is the focus of Biomica Ltd.?
Biomica Ltd. focuses on developing microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
What recent partnerships has Evogene engaged in?
Evogene recently extended validation trials for Lavie Bio's biofungicides with Bayer AG, and secured new seed production agreements for Casterra.
How is Evogene addressing its Nasdaq listing compliance?
Evogene is actively working to regain compliance with Nasdaq's listing requirements and considers various options, including reverse share splits, to maintain its listing.
What are some recent achievements of Evogene Ltd.?
Evogene has advanced clinical trials for Biomica's BMC128, secured new seed production agreements for Casterra, and extended biofungicide validation trials with Bayer AG.
Where can I find more information about Evogene Ltd.?
More information about Evogene Ltd. can be found on their official website at www.evogene.com.
What market segments does Evogene target?
Evogene targets human health, agriculture, and industrial applications through its computational biology platforms and subsidiaries.
EVOGENE LTD.